Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1526 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
BRIEF COMMUNICATION
Year : 2012  |  Volume : 16  |  Issue : 5  |  Page : 815-816

Too short and too poor: A tale of two siblings


Department of Pediatrics, MGMC and RI, Pillaiyarkuppam, Puducherry, India

Date of Web Publication6-Sep-2012

Correspondence Address:
Chandrasekaran Venkatesh
Department of Pediatrics, Mahatma Gandhi Medical College and Research Institute, Pillaiyarkuppam, Puducherry - 607 402
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.100633

Rights and Permissions
   Abstract 

Two short siblings who were brought for evaluation of short stature are described with emphasis on availability of resources in the diagnosis and management of the cause of short stature in them.

Keywords: Growth hormone resistance, mecasermin, short stature, siblings


How to cite this article:
Balaji L, Venkatesh C, Chhavi N, Gunasekaran D, Soundararajan P. Too short and too poor: A tale of two siblings. Indian J Endocr Metab 2012;16:815-6

How to cite this URL:
Balaji L, Venkatesh C, Chhavi N, Gunasekaran D, Soundararajan P. Too short and too poor: A tale of two siblings. Indian J Endocr Metab [serial online] 2012 [cited 2021 Jan 26];16:815-6. Available from: https://www.ijem.in/text.asp?2012/16/5/815/100633


   Introduction Top


Chronic diseases cause huge economic burden to both patients as well as the society at large in terms of costs involved in investigations and treatment over a longer period of time and also loss of national productivity due to sick absenteeism. They also cause emotional distress and domestic turmoil. Chronic childhood diseases are no exception to it. The decision to treat such patients on a long-term basis is often made depending on economics rather than individual choices especially in resource limited settings. We describe two siblings with short stature whose management were complicated by lack of resources.


   Brief Report Top


An 18-month-old male infant was brought with complaints of not gaining height since birth. He was found to be small at birth with uneventful antenatal and natal periods and was delivered at term. His birth weight was normal. Subsequently, around 1 year of age his mother noticed that he was short compared to his peers in the neighborhood. His elder sibling is a 20-year-old girl with height age that corresponds to 5 years (107 cms). The parents had not taken any steps to investigate or treat her elder child because of ignorance and poverty. The girl's intelligence is reportedly normal and has been educated upto higher secondary grade. There is no family history of constitutional delay in growth or puberty. The father's height was 153.5 cm and mother's height was 148.5 cm and mid-parental height of 157.5 cm.

On examination, the boy weighed 7 kg [less than 3 rd centile of world health organization (WHO) weight for age chart], appeared short with height of 63 cm (less than 3 rd centile of WHO height for age chart) with advanced upper segment (US)/lower segment (LS) ratio for age. His mid arm circumference was 13 cm. He showed features of poor mid-facial growth, and prominent head with rounded occiput and small mandible. His hair was sparse brown and silky. He was alert and interacted well with us on examination. There were no teeth abnormalities or stigmata of chronic disease. His elder sibling too shared the above clinical features. He had been earlier hospitalized and investigated for his short stature with funds pooled in from residents and faculty members and the investigations revealed normal bone age, normal thyroid status and an elevated basal growth hormone (GH) levels (49 ng/ dl), decreased IGF-I level of less than 25 (55-327) mg/ml and decreased IGF 1-BP3 level of less than 0.5 (0.7-3.6) u/g ml. Considering the family history of short stature, the typical facial appearance and elevated basal GH levels and reduced IGF-1 level, a provisional diagnosis of GH insensitivity was made. A GH stimulation test and IGF-1 generation test were planned but could not be done as the parents declined it due to economic reasons. Considering the financial background of the child, we were unable to provide any pharmacological support. We had planned to improve the child's nutrition intake and would like to refer him to a place where treatment could be made available free of cost.


   Discussion Top


The child described in our case report was diagnosed to have Laron syndrome based on typical facial features, growth deficiency with increased basal GH levels and decreased IGF-1 and IGF1-BP3 levels with history of similar features in the child's elder sibling. The clinical features in our case is consistent with the description of Laron`s series of 60 Israeli patients with the syndrome named after him. [1] However, in his series, other abnormalities in the form of hypoglycemia, under developed external genitalia, delayed or defective dentition are also described. In our case even though the weight was less than third centile, he did not appear wasted and had relatively preserved subcutaneous fat. That could also explain finding a normal mid-arm circumference in the child. Children with this syndrome appear to be obese in spite of having lower weight for age. We were not able to document hypoglycemia in our child probably because the child was fed on the breast frequently. Laron syndrome is also designated as GH insensitivity syndrome as primarily there is resistance to the action of GH. [2] Recombinant IGF-1 (Mecasermin) is commercially available for treatment of GH insensitivity and disorders of GH-IGF-1 axis for more than 20 years. [3] However, its long-term safety and efficacy is yet to be proved. [4] Treatment of GH insensitivity involves twice daily subcutaneous injection of mecasermin which might cost more than 15 lakh rupees per year of treatment for a child weighing 20 kg. [5]

The diagnosis and treatment of diseases involving GH-IGF-1 axis itself is quite expensive and particularly out of reach for most economically down trodden population for whom expenditure for a life-saving treatment would be more appropriate rather than spending a considerable amount of their savings on diagnosing and if at all treating a condition that does not affect longevity. [6] In the United States, the estimated cost of treating slow growing children between the ages of 4 and 15 years were found to be ranging from 196 million to 18 billion USD depending on whether or not GH therapy is prescribed for one or more of the following three conditions namely GH Deficiency, Turner's syndrome and chronic renal insufficiency. [7] So can we expect to use few lakhs of government money to help these children grow a few inches? Does the above treatment produce a definite improvement in the quality of life in these children? Will the insurance companies in India be able to take care of the costs involved? Even in the west, only about 50% of the patients who have been prescribed GH therapy are actually covered by the insurance companies. [7]


   Conclusions Top


Considering all the above facts it seems counter-productive to spend on investigations when one will not be able to treat. Hopefully, the Pediatric Endocrinology Society of India, the Indian Journal of Endocrinology and Metabolism or the Endocrine Society of India can provide us some guidelines that might help us to choose our resources wisely and economically. Support groups with grants in aid from corporate houses can also be set up to help these children to grow. All said and done in a country where several thousand children are still malnourished and die of its consequences, one might really think whether it is cost-effective to spend several millions just to help a few hundreds to achieve few centimeters of height.

 
   References Top

1.Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): The personal experience 1958-2003. J Clin Endocrinol Metab 2004;89:1031-44.  Back to cited text no. 1
[PUBMED]    
2.Laron Z, Blum W, Chatelain P, Ranke M, Rosenfeld R, Savage M, et al. Classification of growth hormone insensitivity syndrome. J Pediatr 1993;122:241.  Back to cited text no. 2
[PUBMED]    
3.Rosenbloom AL. Mecasermin (recombinant human insulin like growth factor. Adv Ther 2009;26:40-54.  Back to cited text no. 3
[PUBMED]    
4.Kemp SF, Fowlkes JL, Thrailkill KM. Efficacy and safety of mecasermin rinfabate. Expert Opin Biol Ther 2006;6:533-8.  Back to cited text no. 4
[PUBMED]    
5.Ranke MB, Wolfle J, Schnabel D, Bettendorf M. Treatment of dwarfism with recombinant insulin like growth factor-1. Dtsch Arztebl Int 2009;106:703-9.  Back to cited text no. 5
    
6.Laron Z. The GH-IGF-1 axis and longevity. The paradigm of IGF-1 deficiency. Hormones (Athens) 2008;7:24-7.  Back to cited text no. 6
[PUBMED]    
7.Finkelstein BS, Silvers JB, Marrero U, Neuhauser D, Cuttler L. Insurance coverage, physician recommendations, and access to emerging treatments: Growth hormone therapy for childhood short stature. JAMA 1998;279:663-8.  Back to cited text no. 7
[PUBMED]    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Brief Report
   Discussion
   Conclusions
    References

 Article Access Statistics
    Viewed1078    
    Printed43    
    Emailed0    
    PDF Downloaded235    
    Comments [Add]    

Recommend this journal